SKCa- and Kv1-type potassium channels and cancer: Promising therapeutic targets?

Maryne Dupuy1, Maxime Gueguinou2, Marie Potier-Cartereau2

  • 1Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000 Nantes, France.

Biochemical Pharmacology
|September 7, 2023
PubMed

Insights

This review explores how potassium channels, crucial for cell function, are implicated in cancer development. Understanding these oncochannelopathies offers new insights into cancer progression and potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Ion channels are vital transmembrane proteins regulating ion transport across cellular membranes.
  • Dysregulated ion channel expression is linked to key cancer hallmarks like proliferation, apoptosis resistance, and metastasis.
  • Cancers driven by ion channel dysfunction are termed oncochannelopathies.

Purpose of the Study:

  • To provide an overview of plasma membrane potassium channels in cancer.
  • To describe potassium channel nomenclature, structure, and their role in tumor-promoting functions.
  • To highlight the involvement of SKCa- and Kv1- potassium channels in cancer progression.

Main Methods:

  • Literature review focusing on potassium channels and cancer.
  • Analysis of existing research on ion channel function in tumor biology.
  • Specific examination of SKCa- and Kv1- channel roles in cancer progression.

Main Results:

  • Potassium channels are a large, diverse family of ion channels with significant roles in cancer.
  • Aberrant potassium channel activity promotes cancer cell proliferation, migration, and survival.
  • SKCa- and Kv1- channels are specifically implicated in advancing cancer progression.

Conclusions:

  • Plasma membrane potassium channels are critical regulators of cancer cell behavior.
  • Targeting specific potassium channels presents a potential strategy for cancer therapy.
  • Further research into oncochannelopathies, particularly potassium channels, is warranted.

Related Concept Videos

Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
8.3K
Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
190
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
210